Debmalya  Barh Author of Evaluating Organization Development

Debmalya Barh

Institute of Integrative Omics and Applied Biotechnology - IIOAB

We work towards integrative omics based target and targeted drug discovery, biomarkers, pharmacogenomics, cancer, neuro, CVDs, infectious, and metabolic diseases, and plant, animal, and environmental biotechnology


A dynamic ‘Research and Management Professional’ with more than 12+ years’ rich academic and  industry experience in the field of Biotechnology, Bioinformatics, Interdisciplinary Omics, Disease, Biomedical, Healthcare, and IPR. Founder and PI of Institute of Integrative Omics and Applied Biotechnology (IIOAB)-India and currently works with more than 400 colleagues from nearly 100 labs/institutes from 30-35 countries.



1. Barh D, Parida S. Parida BP, Viswanathan G. [2008]. Let-7, miR-125, miR-205, and miR-296 are prospective therapeutic agents in breast cancer molecular medicine. Gene Therapy and Molecular Biology; 12, 189-206.

2. Barh D. [2009]. Biomarkers, critical disease pathways, drug targets, and alternative medicine in male breast cancer. Current Drug Targets; 10, 1-8. [PubMed: 19149530]

3. Barh D, Kumar A, Chatterjee S, Liloglou T. [2009]. Molecular features, markers, drug targets, and targeted therapeutics in cardiac myxoma. Current Cancer Drug Targets; 9 (6), 705-716.  [PubMed: 19754355]

4. Barh D, Malhotra R, Ravi B, Sindhurani P. [2010]. microRNA Let-7: an emerging next-generation cancer therapeutic. Current Oncology; 17 (1), 70-80. [PubMed: 20179807]

5. Barh D, Agte V, Dhawan D, Agte V, and Padh H: Cancer Biomarkers for Diagnosis, Prognosis, and Therapy. In “Molecular and Cellular Therapeutics”. [2012], ISBN: 9780470748145. Edt by David Whitehouse and Ralph Rapley. John Wiley & Sons Ltd, UK.

6. Barh D, Gupta K, Khatri G, Rahangdale S, Verma A. [2012]. An Integrative Omics Strategy for Identification of Skin Cancer Biomarkers. European Journal of Cancer, 48 (S6), 79.

7. D Barh, N Jain, S Tiwari, JK Field, E Padin-Iruegas, A Ruibal, R López et. al. [2013]. A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer. BMC Genomics 14 (Suppl 6), S5


1. Cerdeira LT, Pinto AC, Cruz Schneider MP, Silva S, Santos AR, Vieira Barbosa EG, Ali A, Barbosa MS, Carneiro AR, Jucá Ramos RT, Santos O, Barh D, Barve N, Zambare V, Estevão S, Guimarães LC, de Castro S, Dorella FA, Rocha FS, Augusto V, Tauch A, Trost E, Miyoshi A, Azevedo V, Silva A. [2011]. Whole genome sequence of Corynebacterium pseudotuberculosis PAT10 of strain isolated from sheep in Patagonia, Argentine. Journal of Bacteriology, 193(22):6420-1. [PubMed: 22038974]

2. Cerdeira LT, Carneiro AR, Bol E, Barbosa MS, Coimbra N, Ramos RTJ, Almeida SS, Santos AR, Soares SC, Pinto AC, Ali A, Barbosa E, Dorella FA, Rocha FS, Guimaraes LG, Figueira F, Ghosh P, Zambare V, Barve N, Tiwari S, Barh D, Miyoshi A, Schneider MPC, Azevedo V, Silva A. [2011]. Complete Genome Sequence of Corynebacterium pseudotuberculosis strain - CIP 52.97- isolated from Horse in Kenya. Journal of Bacteriology, 193(24):7025-6. [PubMed: 22123771]

3. Hassan SS, Schneider MP, Ramos RT, Carneiro AR, Ranieri A, Guimarães LC, Ali A, Bakhtiar SM, Pereira Ude P, Dos Santos AR, Soares Sde C, Dorella F, Pinto AC, Ribeiro D, Barbosa MS, Almeida S, Abreu V, Aburjaile F, Fiaux K, Barbosa E, Diniz C, Rocha FS, Saxena R, Tiwari S, Zambare V, Ghosh P, Pacheco LG, Dowson CG, Kumar A, Barh D, Miyoshi A, Azevedo V, Silva A. Whole-Genome Sequence of Corynebacterium pseudotuberculosis Strain Cp162, Isolated from Camel.J Bacteriol. [2012], 194(20):5718-9. [PubMed: 23012291]

4. 8 Genome sequences: GenBank: CP003061; GenBank: CP002924.1; GenBank: CP003077.1; GenBank: CP003385.1; GenBank: CP003407.1; GenBank:  CP003421.1; GenBank:  CP003540.1; GenBank:CP003652.1


1. Barh D and Kumar A. [2009]. In silico identification of candidate drug and vaccine targets from various pathways in Neisseria gonorrhoeae. In Silico Biol.; Vol. 9, 0019. [PubMed: 20109152]

2. Barh D, Misra AN, Kumar A, Vasco A. [2010]. A novel strategy of epitope design in Neisseria gonorrhoeae. Bioinformation; 5 (2), 77-85. [PubMed: 21346868]

3. Barh D, Jain N, Tiwari S, Parida BP, D'Afonseca V, Li L, Ali A, Santos AR, Guimarães LC, de Castro Soares S, Miyoshi A, Bhattacharjee A, Misra AN, Silva A, Kumar A, Azevedo V. [2011]. A novel comparative genomics analysis for common drug and vaccine targets in Corynebacterium pseudotuberculosis and other CMN group of human pathogens. Chemical Biology & Drug Design; 78(1):73-84.  [PubMed: 21443692]

4. Santos AR, Carneiro A, Gala-García A, Pinto A, Barh D, Barbosa E, Aburjaile F, Dorella F, Rocha F, Guimarães L, Zurita-Turk M, Ramos R, Almeida S, Soares S, Pereira U, Abreu VC, Silva A, Miyoshi A, Azevedo V. The Corynebacterium pseudotuberculosis in silico predicted pan-exoproteome. [2012], BMC Genomics. 5:S6. [PubMed: 23095951]

5.Barh D, Barve N, Gupta K, Chandra S, Jain N, et al. [2013]. Exoproteome and Secretome Derived Broad Spectrum Novel Drug and Vaccine Candidates in Vibrio cholerae Targeted by Piper betel Derived Compounds. PLoS ONE 8(1): e52773. doi:10.1371/journal.pone.0052773

6. Barh D, Gupta K, Jain N, Khatri G, León-Sicairos N, Canizalez-Roman A, Tiwari S, et al. [2013]. Conserved host–pathogen PPIs: Globally conserved inter-species bacterial PPIs based conserved host-pathogen interactome derived novel target in C. pseudotuberculosis, C. diphtheriae, M. tuberculosis, C. ulcerans, Y. pestis, and E. coli targeted by Piper betel compounds. Integrative Biology;   [PubMed: 23288366 ] DOI: 10.1039/C2IB20206A [IF: 4.5] NEW

7. Barh D, Barve N, Gupta K, Chandra S, Jain N, Tiwari S, Leon-Sicairos N, Canizalez-Roman A, et al. [2013]. Exoproteome and Secretome Derived Broad Spectrum Novel Drug and Vaccine Candidates in Vibrio cholerae Targeted by Piper betel Derived Compounds.PLOS ONE [PubMed: 23382822]. 2013;8(1):e52773. doi: 10.1371/journal.pone.0052773.


1.Blum K, Chen TJH, Bailey J, Bowirrat A, Femino J, Chen ALC, Madigan M, Simpatico T, Morse S, Giordano J, Damle U, Kerner M, Braverman ER, Fornari F, Downs BW, Rector C, Barh D, Berman MC. Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential? Molecular Neurobiology, 44(3):250-68. [PubMed: 21948099]  

2. Blum K, Chen ALC, Oscar-Berman M, Chen TJH, Lubar J, White N, Lubar J, Bowirrat A, Braverman E, Schoolfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C, Kerner MM, Knopf J, Palomo T, Giordano JJ, Morse SA, Fornari F, Barh D, Femino J, Bailey JA.  [2011]. Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects: Selecting Appropriate Phenotypes for Reward Dependence Behaviors. Int J Env Res Public Health; 8(12):4425-4459. [PubMed: 22408582]

3. Chen ALC, Blum K, Chen TJH, Giordano J, Downs BW, Han D, Barh D, Braverman ER. [2012]. Correlation of the Taq1 Dopamine D2 Receptor Gene and Percent Body Fat in Obese and Screened Control Subjects: A Preliminary Report. Food & Function; 3(1):40-8. [PubMed: 22051885]

4. Blum K, Chen ALC, Giordano J, Borsten J, Chen TJH, Hauser M, Simpatico T, Femino J, Braverman ER, Barh D. The Addictive Brain: All Roads Lead to Dopamine. Journal of Psychoactive Drugs, [2012], 44 (2), 134–143. [PubMed: 22880541]

5. Miller M, Chen A, Stokes S, Silverman S, Bowirrat A, Manka M, Manka D, Miller D, Perrine K, Chen T, Bailey J, Downs BW, Waite R, Madigan M, Braverman E, Damle U, Kerner M, Giordano J,  Morse S, Oscar-Berman M, Barh D, Blum K. Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study. Journal of Psychoactive Drugs [2012], DOI:10.1080/02791072.2012.737727


1. Hollmann A, Saviello M, Delfederico L, Saraiva TDL, Barh D, Chandra S, Gupta K, Jain N, Zambare V, Kumar A, Misra AN, Christopher L, Azevedo V, Semorile L, Miyoshi A. [2012]. Tight controlled expression and secretion of Lactobacillus brevis SlpA in Lactococcus lactis. Biotechnology Letters. [PubMed: 22391736]

2. Zambare V. Zambare A, Barh D, Christopher LP. Optimization of enzymatic hydrolysis of prairie cordgrass for improved ethanol production. J. Renewable Sustainable Energy, [2012], 4, 033118

3. Barh D, Ahmad S, and Bhattacharjee A: In silico and ultra-high throughput screenings (uHTS) in drug discovery: an overview. In “Pharmaceutical Biotechnology (2nd Ed)”, [2012], ISBN: 978-3-527-32994-6. Edt by Oliver Kayser and Herbert Warzecha. Wiley-VCH Verlag GmbH & Co, Germany.

4. Hemaiswarya S, Raja R, Isabel  SC, Ravikumar R, Zambare V, Barh D. An Indian scenario on renewable and sustainable energy sources with emphasis on algae. Appl Microbiol Biotechnol [2012], DOI 10.1007/s00253-012-4487-0, [PubMed: 23070650]

5. Barh D, Yiannakopoulou UC, SALAWU UO, Bhattacharjee A, Chowbina S, Ghosh P, Azevedo V: In silico disease models. In “Animal Biotechnology: Models in Discovery and Translation”, [2012], Edt by Verma and Singh. Elsevier, USA (In Press)

Areas of Research / Professional Expertise

    Bioinformatics, Integrative omics based target and targeted drug discovery, pharmacogenomics, cancer, neuro, CVDs, metabolic diseases, and plant, animal, and environmental biotechnology



Featured Title
 Featured Title - Noninvasive Molecular Markers in Gynecologic Cancers - 1st Edition book cover